1. Home
  2. NAMS

NAMS

NewAmsterdam Pharma Company N.V.

Logo NewAmsterdam Pharma Company N.V.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Founded: 2019 Country:
Netherlands
Netherlands
Employees: N/A City: NARRDEN
Market Cap: 1.9B IPO Year: N/A
Target Price: $33.25 AVG Volume (30 days): 240.1K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.30 EPS Growth: N/A
52 Week Low/High: $5.63 - $26.35 Next Earning Date: 03-31-2023
Revenue: $15,655,556 Revenue Growth: N/A
Revenue Growth (this year): 340.04% Revenue Growth (next year): -82.44%

Share on Social Networks: